semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Aspergillosis The patient or legally authorized representative has signed an informed consent/assent Assent will be obtained as required by the UAMS IRB The patient has a diagnosis of proven or probable invasive aspergillosis and with positive Aspergillus GM index (≥0.5 ng/ml) provide the patient is not receiving antibiotics, such as piperacillin-tazobactam, that are known to cause false positive GMI The patient is 18 years of age or older  The patient is being treated with an unlicensed investigational drug for aspergillosis The patient has been administered an antifungal agent (voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B, or lipid formulation of amphotericin B) for > 7 days immediately prior to randomization for treatment of the Probable, or Proven invasive aspergillosis for which the patient is being enrolled Patient has invasive aspergillosis but with negative Aspergillus GM index The patient is pregnant or lactating. If the patient is female and of childbearing potential, the patient must have a negative pregnancy test and avoid becoming pregnant while receiving study drug. A pregnancy test should be performed within 14 days prior to the first dose of study drug The patient has alkaline phosphatase, ALT, AST or total bilirubin greater than five times the upper limit of normal The patient has hepatic cirrhosis Patients with creatinine > 3 will be enrolled only if able to receive oral voriconazole (specify oral loading dose is 6 mg/kg PO Q 12 hours for 24 hours) then oral maintenance 200 mg PO q 12 hours) The patient is on artificial ventilation, and unlikely to be extubated within 24 hours of study entry The patient has a history of allergy, hypersensitivity, or any serious reaction to the azole or echinocandin class of antifungal agents The patient has previously enrolled into this study
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Cystic Fibrosis Allergic Bronchopulmonary Aspergillosis A. Fumigatus Male or female ≥ 12 years of age at enrollment Confirmed diagnosis of CF based on the following One or more clinical features consistent with the CF phenotype AND (b or c) Positive sweat chloride > 60 mEq/liter (by pilocarpine iontophoresis) two identifiable mutations consistent with CF Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study Clinically stable at enrollment as assessed by the site investigator Past or present respiratory culture positive for Aspergillus fumigatus IgE ≥ 250 and/or presence of class II or higher aspergillus specific IgE on enrollment Ability to comply with medication use, study visits and study procedures as judged by the site investigator -  Systemic corticosteroids (1 mg/kg if < 20 kg or > 20 mg of prednisone per day) Investigational drug use within 30 days of screening 3. Laboratory abnormalities at screening a. Serum Calcium > 11 mg/dl b. 25(OH) D > 50 ng/ml at screening. c. Creatinine ≥ 1.5, or estimated GFR <60 by Cockcroft-Gault or MDRD equation. d. LFT≥ 3xULN History of transplantation or currently on lung transplant list 5. Positive serum pregnancy test at screening (to be performed on all post-menarche females) 6. Pregnant, breastfeeding, or if post-menarche female, unwilling to practice birth control during participation in the study 7. Presence of a condition or abnormality that in the opinion of the site investigator would compromise the safety of the subject or the quality of the data 8. Diagnosis of HIV and a CD4+ T cell count below 500 cells/ml or active hepatitis B or C infection Undergoing therapy for non-tuberculous mycobacterial infection
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Invasive Pulmonary Aspergillosis hospitalisation in the hematology or intensive care department age > 16 years informed consent proven or probable IPA (EORTC/ MSG criteria) galactomannan positivity in BAL or serum  age < 16 years
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Transplant Recipient Single or double lung transplant recipients who are at least one year out of transplantation Age >18yrs of age Able to understand and complete informed consent  Pregnant woman or woman capable of bearing children, who will not perform urine pregnancy test Nursing mothers Subjects with hypersensitivity to Amphotericin deoxycholate or liposomal Amphotericin Subjects with a past history of bronchospasm associated with aerosol drug use Subjects with active bacterial or viral infection as defined by the current use of non-prophylactic antibiotic anti-viral medications Subjects treated with cytolytic medications (Campath /Thymoglobulin) within the last month Subjects with an FEV1< 30% Predicted or FVC% <30% Subjects requiring supplemental oxygen Receipt of Inhaled or IV Amphotericin B within last 30 days Subjects with known fungal infection as per MSG on therapy with antifungal drugs or diagnosed on the day of bronchoscopy
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 14.0-80.0,  Chronic Cavitary Pulmonary Aspergillosis Clinical symptoms: -presence of chronic pulmonary/systemic symptoms lasting ≥ six weeks Radiological findings Evidence of slowly progressive pulmonary lesions over weeks-months including cavities with surrounding inflammation presence of intracavitary mass with a surrounding crescent of air,and presence of pleural thickening in peripheral lesions Microbiological/Immunological findings: Positive results in the aspergillus precipitin test, demonstration of aspergillus hyphae in sputum or BAL fluid or cultures of BAL/sputum growing aspergillus species The diagnosis of CCPA will be made if Patient satisfies at least 1, 2a or 2b and/ or any of the 3rd criteria FNAC from the cavity wall will be considered in atypical cases  Invasive aspergillosis Allergic broncho-pulmonary aspergillosis (ABPA) Active tuberculosis or malignancy Pregnant females
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infection The for participants to enter the study mandates that each patient have received a standard (current clinical practice) diagnostic evaluation that includes a CT scan of the chest to document bronchiectasis, prior to enrolling in the Consortium study. To enter this protocol, adults must have bronchiectasis and meet the following Males or females, age greater than or equal to18 years Chronic cough An available CT of the chest (on a CD) that shows evidence of dilated airways fulfilling radiographic for bronchiectasis in more than one lobe Ability to provide informed consent, including HIPAA consent  A participant should not be in the study if they have not had a standard clinical evaluation to rule out other potential causes of chronic sino-pulmonary disease Known diagnosis of cystic fibrosis with classic clinical presentation and elevated sweat chloride levels and/or two known disease-causing CFTR mutations History of tuberculosis or other known explanation for bronchiectasis, such as alpha 1-antitrypsin deficiency (ZZ or ZS), confirmed or probable PCD, inflammatory bowel disease, rheumatoid arthritis, Sjogren s syndrome, allergic bronchopulmonary aspergillosis, or documented primary or acquired immunodeficiency Current smoker or > 10 pack-year history of tobacco use Prior solid organ transplant
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 0.083-14.0,  Tuberculosis Any child with at least one of the following Unexplained weight loss or documented failure to thrive or stagnant weight or Growth faltering on the growth charts over the past 3 months despite adequate nutrition and deworming Non remittent cough or wheeze for more than 2 weeks Night sweats persistent or intermittent during the last 2 weeks Prolonged fever (temperature > 38°C) for 7 days, after common causes such malaria or pneumonia has been excluded Wheeze/Stridor persistent, non remitting during the last 2 weeks Chest pain Persistent, localized, pleuritic in nature during the last 2 weeks  Current TB treatment (patient who received < 3 days of treatment or patients receiving IPT could be still included) or TB treatment completed within the past 6 months Absence of informed consent Living outside of Greater Mbarara region Unable or unwilling to attend to the follow-up visits
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 5.0-80.0,  Invasive Aspergillosis hematological patients with lung infiltrates at high risk for invasive aspergillosis  patients without informed consent
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 5.0-85.0,  Invasive Aspergillosis immunocomprimised patients with high risk of invasive aspergillosis and lung infiltrates informed consent  Children under the age of 5 years Informed consent not available
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Ventilator Associated Pneumonia All adult patients above 18 years old admitted into the Intensive Care unit and who is to be intubated and likely to receive more than 72 hours of ventilation would be admitted into the trial  presence of cavitary lung disease based on chest x-ray findings primary lung cancer or another metastatic malignancy to the lungs, or known or suspected viral or fungal etiology pneumocystis carinii pneumonia legionella OR Mycoplasma pneumonia or active tuberculosis
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cystic Fibrosis Healthy control subjects Age 18-65 No history of lung disease Cystic fibrosis subjects Age 18-65 No history of lung disease other than cystic fibrosis Diagnosis of CF if sweat chloride values > 60 mM on two separate pilocarpine iontophoresis sweat tests and/or two allelic CF-producing mutations in genetic analysis  Use of recreational drugs within 30 days prior to enrollment Use of tobacco within 30 days prior to enrollment, or > 10 pack-year tobacco history Pregnant or lactating females
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Scalp Psoriasis Plaque Psoriasis Capable of giving informed consent and the consent must be obtained prior to any study related procedures Be 18 years of age or older at the time of consent; may be male or female Have had a diagnosis of plaque psoriasis at least 6 months prior to administration of study agent Presence of moderate or severe psoriasis on the body other than the scalp At least 30% of scalp affected with erythema, induration and desquamation and s-PGA score greater than or equal to 4 Be candidates for phototherapy or systemic treatment of psoriasis Women of childbearing potential and all men must be using adequate birth control measures (eg abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) and must agree to continue use of such measures and not become pregnant or plan a pregnancy until 12 months after receiving the last injection of study agent Be able to adhere to protocol requirements and study visit schedule Must agree not to receive a live virus or live bacterial vaccination during the trial and 12 months after last study injection Must agree not to receive a BCG vaccination during the trial and up to 12 months after the last injection  Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current, active TB or old, inactive TB Have screening laboratory test results within the following parameters Hemoglobin > 10g/dL White Blood Cells > 3.5 x 109 /L Neutrophils > 1.5 x 109 /L Platelets > 100 X109 /L Serum Creatinine < 1.5 mg/dL ( or 133 micromol/L ) AST,ALT, and alkaline phosphatase levels must be within 1.5 times the upper limit of normal range for the laboratory conducting the test Subjects meeting any of the following may not be enrolled in the study Currently have non-plaque forms of psoriasis (erythrodermic, guttate, or pustular)
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Cystic Fibrosis Aspergillus Infections Patient with cystic fibrosis men or women age equal greater to 12 years presenting with a positive sputum culture for Aspergillus confirmed twice within 6 months before study entry and at initial visit written informed consent  patients with a contraindication to one of the antifungal agents evaluated pregnant women or nursing mothers absence of an effective method of contraception in women of child-bearing potential patients with signs or symptoms of invasive aspergillosis patients with signs or symptoms of aspergilloma patients with an infection caused by Burkholderia complex Cepacia or to mycobacteria lung transplant patients, registered on a transplantation waiting list or whose registration is imminent patients who received systemic antifungal therapy for more than 5 days within 2 months prior to patients currently enrolled in another clinical drug trial ongoing treatment with medicinal products contraindicated with itraconazole and voriconazole or with major interactions which reduce azole concentrations
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 3.0-17.0,  Invasive Pulmonary Aspergillosis Lymphoblastic Leukaemia Myeloblastic Leukaemia Lymphoblastic Leukemia Myeloblastic Leukemia Age: patients between 3 and 18 years Diagnosis of myeloblastic or lymphoblastic AL during intensive chemotherapy Informed consent of parents/guardians and/or assent of the patient has been obtained  Probable or proven invasive pulmonary fungal infection before entering the trial Previous chronic renal impairment or baseline serum creatinine > 2.5 mg /dL Severe hepatic impairment Moderate-severe asthma being treated pharmacologically Antifungal treatment for filamentous fungi in the last 4 weeks Participating or have participated in a clinical trial during the last 4 weeks Mentally retarded Known allergy or hypersensitivity to the active ingredient of the study drug or to any of its excipients Any serious concomitant disease that in the investigator's opinion could compromise the completion of the trial or affect the patient's tolerability to this treatment Pregnancy (in women of fertile age)
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Pulmonary Tuberculosis (TB) HIV negative patients, adult patients >18 years who has not started anti-TB therapy Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative clinical TB cases (defined according to the WHO 2006 for sputum smear-negative TB ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment)  Patients who have already started treatment with anti-TB drugs for more that 5 days HIV-positive patients History of anti-TB treatment in the past 2 years Local extra-pulmonary TB in the absence of lung manifestations Hypercalcaemia (serum calcium > 2.6 mmol/L) identified at baseline Pregnant and breast feeding women Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infections Signature of informed consent to participate in the study Adult patients (> 18 years), diagnosed with acute myelogenous leukemia or myelodysplastic syndrome with chemotherapy (CT) intensive, or admitted to undergo allogeneic hematopoietic progenitor cells, or transplantation with graft versus host disease The patient should be included in this protocol from the start of their chemotherapy or conditioning therapy as reflected in another section  Employment of antifungal prophylaxis (30 days prior to inclusion) with triazole / polyene with activity against Aspergillus (itraconazole, voriconazole, posaconazole, amphotericin B inhalation) Use of other systemic antifungal activity against Aspergillus (amphotericin, terbinafine, flucytosine, echinocandins, etc.). Therefore it will Fluconazole prophylaxis exclusively Background of IFI proven / probable prior Probable IFI / tested at the time of in the study will cause a lack of compliance with the criteria Patients who have a lack of follow biweekly with galactomannan or PCR. Have a bacterial infection not properly treated and controlled before starting empirical antifungal treatment (according to the definition given above). And finally they have a neutropenia of short duration that it creates a significant risk of IFI. This information will not be known logically to the patient in the study
Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 1.0-16.0,  Pediatric Urinary Lithiasis The patients with pediatric urinary lithiasis  Resistant urinary tract infections Coagulopathies Anatomically obstructed urinary system